IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
As previously disclosed by the Company on a Current Report on
Form 8-K filed with the Securities and Exchange Commission on May
26, 2017, Nasdaqs Hearing Panel (the Panel) had notified the
Company of deficiencies to Nasdaqs Listing Rule 5250(c)(1) (the
Rule) on April 18, 2017 and May 23, 2017, due to its failure to
timely file its Form 10-K for the year ended December 31, 2016
and its Form 10-Q for the period ended March 31, 2017 (First
Quarter Report). On May 10, 2017, the Company provided a
submission to the Panel explaining the reason for the late
filings and asking that the Panel extend its listing through June
15, 2017. The Panel delayed a decision on that issue until after
May 17, 2017, the date by which the Company represented it would
file its delinquent Form 10-K. The Company filed the delinquent
annual report on May 17, 2017, as acknowledged by the Panel, and
informed the Panel shortly thereafter that it was on target to
file the late Form 10-Q and regain compliance with the filing
Rule by June 15, 2017. The Company filed its delinquent First
Quarter Report on Form 10-Q on June 14, 2017.
Accordingly, the Panel has confirmed by letter, dated June 15,
2017, that the Company has regained compliance with Nasdaqs
Listing Rule 5250(c)(1) and is in compliance with other
applicable requirements as set forth in the decision and required
for listing on The Nasdaq Stock Market, and has closed this
matter.
| Item 8.01 | Other Events |
On June 19, 2017, the Company issued a press release announcing
compliance with the Rule and the Companys continued listing on
the Nasdaq Stock Market. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
99.1 Press Release issued by Immune Pharmaceuticals on June 19,
2017.
IMMUNE PHARMACEUTICALS INC ExhibitEX-99.1 2 v469366_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Receives NASDAQ Compliance Letter NEW YORK,…To view the full exhibit click here About IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP)
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
